ElevateBio nabs $535M to advance CGT technologies

By The Science Advisory Board staff writers

March 15, 2021 -- ElevateBio has raised $535 million in financing to advance its cell and gene therapy (CGT) technology platforms, build its network of process development and good manufacturing practice (GMP) manufacturing capacity, and increase its number of industry partnerships.

ElevateBio has created a suite of CGT-enabling technologies, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering technologies. The company is advancing CGTs using its technology-enabled process development and current GMP (cGMP) manufacturing capability, called BaseCamp.

Matrix Capital Management led the series C financing.

LifeEdit Therapeutics joins ElevateBio's gene editing portfolio
Cell and gene therapy accelerator ElevateBio has added LifeEdit Therapeutics to the company's portfolio of therapeutic, technology, and manufacturing...

Copyright © 2021 scienceboard.net

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter